Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review

Table 1 Study characteristics

Ref.	Study design	Patient population	Intervention	Comparator	Efficacy endpoint	Efficacy outcome time-point
Lingvay et al[25]	Multinational, multicentre, 26-wk, randomised, open-label, 2-group, treat-to-target trial	Adults with type 2 diabetes	Insulin degludec/liraglutide	Insulin glargine U100	Baseline HbA1c level was 8.4% for the degludec/liraglutide group and 8.2% for the glargine group. HbA1c level reduction was greater with degludec/liraglutide vs glargine [-1.81% for the degludec/liraglutide group vs -1.13% for the glargine group; estimated treatment difference, -0.59% (95%CI: -0.74 to -0.45)], meeting criteria for noninferiority (P < 0.001) and meeting criteria for statistical superiority (P < 0.001)	26-wk
Rosenstock et al[26]	Randomised, open-label, parallel group, multicentre	Adults with type 2 diabetes	iGlarLixi	Insulin Glargine U100	Mean HbA1c was reduced from 8.0% at baseline to 6.3% and 6.5% with LixiLan and Gla-100, respectively, establishing statistical noninferiority and superiority of LixiLan [least-squared mean (95%CI) difference: -0.17% (-0.31, -0.04) (-1.9 mmol/mol, -3.4, -0.4); P = 0.01]	24-wk
Rosenstock et al[28]	Randomised, parallel, open label, 3-arm-treatment	Adults with type 2 diabetes	iGlarLixi	Insulin glargine U100; Lixisenatide	Greater reductions in HbA1c from baseline (8.1%) were achieved with iGlarLixi compared with iGlar and Lixi (-1.6%, -1.3%, -0.9%, respectively), reaching mean final HbA1c levels of 6.5% for iGlarLixi vs 6.8% and 7.3% for iGlar and Lixi, respectively (both P < 0.0001)	30-wk

CI: Confidence interval; HbA1c: Haemoglobin A1c.